Moleculin Biotech MBRX 深 沪
已收盘 09-12 16:00:00 美东时间
0.3638
-0.012
-3.24%
华盛通- 最 高0.3823
- 今 开0.377
- 成交量 254.88万股
- 最 低 0.36
- 昨 收 0.376
- 总市值 1101.81万
- 52周最高 3.6499
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.25
- 委 比 -98.91%
- 总股本 3028.62万
- 历史最高 862.20
- 量 比 0.71
- 振 幅 5.93%
- 历史最低 0.25
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
Moleculin Biotech announced expansion of its Phase 2B/3 MIRACLE trial for AnnAnnAraC in AML treatment, adding sites in the US, Spain, Georgia, Poland, Romania, Italy, and Lithuania. The company expects to recruit 20 subjects by September and reach 45 by Q4 2025 for initial data unblinding, aiming for Part A completion in early 2026 and Part B launch thereafter. The trial's adaptive design allows early evaluation of efficacy and safety, with optim...
09-09 12:45
Moleculin Biotech Begins Phase 2B/3 MIRACLE Trial Enrollment
Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. On September 8, 20...
09-08 21:03
Moleculin Announces It Has Dosed The First EU Patient In It's Phase 3 MIRACLE Trial For Treatment Of Acute Myeloid Leukemia
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced
09-08 20:31
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Moleculin Biotech has enrolled the first two subjects, with one treated, in its Phase 2B/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (R/R AML) in Spain. The trial aims to recruit 45 subjects by end-2025 for initial data unblinding. Sites are active in the US, Spain, Ukraine, Georgia, and Romania, with more expected by September. The MIRACLE trial, studying Annamycin in combination with cytarabine, targets 45 subjects for early ...
09-08 12:30
Reported Earlier: Moleculin Biotech Raises $6M From Immediate Exercise Of 16.2M Warrants At $0.37/Share; Issues 64.9M New Warrants At $0.55/Share
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has
08-29 00:51
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
Moleculin Biotech, Inc. entered into agreements to exercise warrants for up to 16.2 million shares at $0.37 per share, generating approximately $6 million in gross proceeds. In exchange, the company issued new warrants for up to 64.9 million shares at $0.55 per share, exercisable upon shareholder approval. The transaction is expected to close on August 28, 2025, with proceeds used for working capital and general corporate purposes. Roth Capital P...
08-28 12:30
Moleculin Biotech Completes Phase 1B/2 Clinical Trial Evaluating Annamycin In Combination With Cytarabine For Acute Myeloid Leukemia
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)Median OS of 2nd Line efficacy evaluable population of 12 months (n=9)Median OS of Intent to Treat population (1L-7L) of 9 months
08-27 20:48
Moleculin Issues New Positive AML Overall Survival Data:
Moleculin Biotech announced the completion of its Phase 1B/2 MB-106 trial evaluating Annamycin in combination with Cytarabine for treating acute myeloid leukemia (AML). The trial enrolled 22 subjects, with updated overall survival (OS) data showing a median OS of 15 months for complete remission (CR) patients (n=8), 12 months for the 2L efficacy evaluable population (n=9), and 9 months for the intent-to-treat (ITT) population (n=22). These result...
08-27 12:45
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Moleculin Biotech, Inc. (Nasdaq: MBRX) will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 20, 2025, at 2:00 PM ET. Walter Klemp, Founder, President, CEO, and Chairman, will discuss the Company's progress. Moleculin specializes in developing therapies for hard-to-treat tumors and viruses. Its lead candidate, Annamycin, targets relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma ...
08-14 13:15
Moleculin Biotech GAAP EPS of -$0.49
Moleculin Biotech press release (NASDAQ:MBRX): Q2 GAAP EPS of -$0.49. Cash and cash equivalents of $7.6M More on Moleculin Biotech Moleculin receives notice of intent to grant new European patent fo...
08-13 21:45
